retatrutide fda approval status november 2025 vs Tirzepatide: 28.7% vs 22.5% (2026) Eli Lilly's Phase 3 data

While outside the scope of muscle recovery directly, this body of literature has contributed foundational understanding of BPC-157s proposed stability and systemic activity that informs its use as a research tool in other tissue models

10.1097/prs.0000000000005322 71 MaldonadoA

Capsule (Hydroxypropyl Methylcellulose, Colour (Brilliant Blue)), Anti-Caking Agents (Silicon Dioxide, Magnesium Stearate)

While GLP-1 receptor agonists are traditionally prescribed for type 2 diabetes and weight management, their potential to address hot flashes may open new doors for their use

Tirzepatide, a dual agonist for GLP-1 and GIP receptors, effectively promotes weight loss and improves metabolic parameters by influencing insulin secretion, appetite regulation, and gastric emptying